Zymogenetics, Inc.

Janssen Biotech, Inc.

Bristol-myers Squibb Compnay

Dennis L Dong

Paul O Sheppard

Kevin M Klucher

Thomas R Bukowski

Lowell J Brady

Chung Chan

Hong Yan Liu

Hong Liu

Chung-Leung Chan

Pedro Alfonso

Michael Capaldi

Thomas R Gervais

Joshua Goldstein

Allen B Magill

Nicole Quinlan

Deepak Saini

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Mutants of IL-29

Methods useful for producing a solution of purified Fc peptide chains are disclosed. The methods employ protein A chromatography to separate high molecular weight, aggregated peptide chains comprising antibody Fc domains from lower molecular weight unaggregated peptide chains that also comprise antibody Fc domains. The solutions of purified Fc peptide chains obtained by the methods of the invention contain less than 5% aggregate and greater than 70% of the Fc peptide chains subjected to purification.

Process for preparing unaggregated antibody Fc domains

Method of using IL-29 cystehne mutant to treat hepatitis C and hepatitis B

Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B

Polynucleotide encoding an IL-28A polypeptide

Polynucleotide encoding an IL-28A polypepide

Polynucleotide encoding an IL-28B polypeptide

Polynucleotide encoding an il-29 polypeptide

Polynucleotide encoding an IL-29 polypeptide

Growing community of inventors

Bellevue, WA, United States of America

Dennis L Dong